CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Amneal Pharmaceuticals LLC

1:15-cv-01025

Overview

Case Number 1:15-cv-01025
Filing Date 2015-11-05
Status Terminated
Termination Date 2016-12-09
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Amneal Pharmaceuticals Co. India Private Limited NPE (University / Research)

Represented By

2 Attorneys Listed

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Samantha G. Wilson

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-5018

Rodney Square, 1000 North King Street

Amneal Pharmaceuticals of New York, LLC Operating Company

Represented By

2 Attorneys Listed

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Samantha G. Wilson

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-5018

Rodney Square, 1000 North King Street

Novartis AG Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

5 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Nicholas N. Kallas

Email: nkallas@venable.com

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Jared L. Stringham

Email: jlstringham@venable.com

Plaintiff

Novartis Pharma AG Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Counter Claimant

Amneal Pharmaceuticals LLC Operating Company

Represented By

2 Attorneys Listed

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Samantha G. Wilson

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-5018

Rodney Square, 1000 North King Street

Counter Defendant

LTS Lohmann Therapie-Systeme AG Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 8 proceedings
🏛️
USPTO PTAB Trials 4 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (12 found):
PTAB: 4 U.S. Courts: 8
USPTO PTAB Trial 2014-11-13
IPR2015-00268

Mylan Pharmaceuticals Inc. et al. v. Novartis AG et al.

U.S. Continuation Sibling (6335031)
Status: Final Written Decision
USPTO PTAB Trial 2014-11-13
IPR2015-00265

Mylan Pharmaceuticals Inc. et al. v. Novartis AG et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2014-04-02
IPR2014-00550

Noven Pharmaceuticals, Inc. et al. v. Novartis AG et al.

U.S. Continuation Sibling (6335031)
Status: Final Written Decision
USPTO PTAB Trial 2014-04-02
IPR2014-00549

Noven Pharmaceuticals, Inc. et al. v. Novartis AG et al.

Asserted Patent
Status: Final Written Decision
U.S. District Court 2015-11-05
1:15-cv-01026

Novartis Pharmaceuticals Corporation v. Dr. Reddy's Laboratories, Ltd.

Asserted Patent
Status: DED
U.S. District Court 2014-06-19
1:14-cv-00777

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-01-30
1:14-cv-00111

Novartis Pharmaceuticals Corporation v. Noven Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-04-03
1:13-cv-00527

Novartis Pharmaceuticals Corporation v. Noven Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-07
1:13-cv-00371

Novartis Pharmaceuticals Corporation v. Actavis Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-07
1:13-cv-00370

Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc.

Asserted Patent
Status: DED
U.S. District Court 2011-11-09
1:11-cv-01112

Novartis Pharmaceuticals Corporation v. Watson Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2011-11-03
1:11-cv-01077

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6316023
TTS containing an antioxidant
Filed: 2000-12-20
Issued: 2001-11-13
Expired (Term Ended)
Expires: 2020-12-20
US6335031
TTS containing an antioxidant
Filed: 1999-04-14
Issued: 2002-01-01
Expired (Term Ended)
Expires: 2019-04-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

7

Dispositive

0

Granted

0

Denied

0

Pending / Review

7

Motions by Category

Procedural / Extension Motion 6 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for the parties to substantially complete document production to November 11, 2016 - filed by Amneal Pharmaceuticals LLC, Amneal Phar...
Entry #41 • 2016-10-07 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for the parties to substantially complete document production, pursuant to Paragraph 3(c) of the Scheduling Order to October 12, 2016...
Entry #40 • 2016-09-06 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to substantially complete document production pursuant to Paragraph 3(c) of the Scheduling Order to September 12, 2016 - filed by Amn...
Entry #38 • 2016-07-13 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to submit a Proposed Protective Order to April 1, 2016 - filed by LTS Lohmann Therapie-Systeme AG, Novartis AG, Novartis Pharma AG, N...
Entry #33 • 2016-03-18 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 7/8/2016. Amended Pleadings due by 7/8/2016....
Entry #26 • 2016-02-17 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION To Extend Time to Answer, Move or Otherwise Respond to the Complaint to December 16, 2015 - filed by Amneal Pharmaceuticals Co. India Private Limite...
Entry #13 • 2015-12-02 Document →

Docket Entries

(61 total)
Pleading / Complaint

COMPLAINT filed against Amneal Pharmaceuticals Co. India Private Limited, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1822460.) - filed by Novartis Pharmaceuticals Corporation, Novartis Pharma AG, LTS Lohmann Therapie-Systeme AG, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(nmb) (Entered: 11/06/2015)

Entry #1 • 2015-11-05
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 11/06/2015)

Entry #2 • 2015-11-05
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/25/2015. Date of Expiration of Patent: 1/8/2019.Thirty Month Stay Deadline: 3/25/2018. (nmb) (Entered: 11/06/2015)

Entry #3 • 2015-11-05
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,316,023; 6,335,031. (nmb) (Entered: 11/06/2015)

Entry #4 • 2015-11-05
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (nmb) (Entered: 11/06/2015)

Entry #5 • 2015-11-05
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc